Notice: Eric Fry Will Reveal His “Nvidia on Steroids” Pick on Wednesday, Sept. 10

Eric Fry has shown his followers more than 40 gains of 1,000% or more already. Now he says a little-known AI robotics stock could be the “Next Nvidia on Steroids.” His new Apogee system flagged it using the same 10X Pattern that appeared before Nvidia’s 1,871% run… Apple’s 4,285% surge… and Amazon’s 1,115% climb during the system’s 5.2 million back-tests. Eric will reveal full details down to the ticker, for free, on Sept. 10.

Wed, September 10 at 10:00AM ET
 
 
 
 
Register Here

Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

For VW and Porsche, a High-Octane Deal

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader
The tie-up will allow both venerable German carmakers to benefit. VW gets another coveted luxury brand, and Porsche gets access to efficient production.

For Europe, Shale Gas Is No Panacea

By Aaron Levitt, InvestorPlace Contributor
Europe has plenty of reserves. Getting them out is the hard part, especially considering the widespread environmental and political opposition to fracking.

Did Kohl’s Rally on a Short Squeeze?

By Dan Burrows, InvestorPlace Feature Writer
Its tempered outlook was still better than the Street's forecast. Given KSS's recent plunge and the high short interest, someone was clearly surprised.

Good News Isn’t Enough: Thursday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
U.S. markets ended the day mostly mixed as strong economic news wasn't enough to build momentum on a slow trading day after the July 4th holiday.

Netflix Reaches Major Streaming Milestone

By Christopher Freeburn, InvestorPlace Writer
Netlflix subscribers watched more than 1 billion hours of streaming video content in June as the company moves away from DVDs-by-mail service.

4 Takeaways From June Auto Sales

By Susan J. Aluise, Aviation, Auto & Transportation Writer
The industry posted a much-stronger month than expected, but global slowdowns bode ill for carmakers.

Gold, Silver Drop After ECB Cuts Lending Rate

By Angela Nazworth, InvestorPlace Writer
A surprise rate cut in China didn't lift prices, either.

Let the Fireworks Begin: Tuesday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Markets rallied on two bits of strong economic news in a holiday-shortened trading session.

What Planet Is RIM’s CEO On?

By Tom Taulli, InvestorPlace Contributor
Despite what Thorsten Heins says, the company is in a “death spiral” and it will be until he comes up with a convincing strategy to stave off disaster.

Barclays: Another Wall Street Game-Fixer

By Dan Burrows, InvestorPlace Feature Writer
Barclays' executives heads rolled after the company received a record fine for rigging LIBOR rates, but the punishment was a pittance compared to the crime.

The ‘Real America Index’: A Better Benchmark

By Alyssa Oursler, InvestorPlace Contributor
Forget the Dow, we created the Real America Index to get a more accurate picture of the U.S. economy. See which 51 stocks we are tracking.

Top 10 Cars Americans Will Not Buy

By Douglas McIntyre, Co-Founder & Editor, 24/7 Wall St.
Poor quality and poor fuel efficiency appear to be hurting sales of the cars on this list.

Shouldn’t Acquisitions Actually Be Worth It?

By James Brumley, InvestorPlace Feature Writer
Microsoft just announced it was flushing $6.2 billion on its 2007 acquisition of aQuantive. Unfortunately, money-sucking deals like this are far from isolated.

Glaxo to Pay $3B in Fines for Improper Drug Marketing

By Christopher Freeburn, InvestorPlace Writer
GlaxoSmithKline will pay $3 billion in fines relating to its promotion of the antidepressant drugs, Paxil, Wellbutrin and Avandia, and the asthma drug Advair.

Wall Street’s Biggest Winners & Losers of Q2

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader
As a whole, energy stocks stunk up Wall Street for the past three months, while utilities smelled like roses. Here's a look at the individual best and worst.

2 D.C.-Area Utilties Battle for Power

By Marc Bastow, InvestorPlace Assistant Editor
With power out in much of the D.C. region, utility companies Dominion and Pepco try to satisfy both customers and shareholders over the coming week.

Gold, Silver Stagnant Despite Talk of QE3

By Angela Nazworth, InvestorPlace Writer
More talk of QE3 spurred by poor manufacturing numbers did little to inspire gold and silver prices Monday. Miners also had a mixed going.

Manufacturing Woes Stop the Mo: Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Markets reacted to a disappointing manufacturing report, starting out in negative territory before coming back for slight gains in the S&P and Nasdaq.

Why McDonald’s Plans to Play Chicken

By InvestorPlace Staff
With new CEO Don Thompson at the helm, McDonald's now has plans to make a surprising menu shift -- less beef, more chicken. Find out why.
Load More Articles